{"id":"NCT00763971","sponsor":"Shire","briefTitle":"Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17","officialTitle":"A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-11-17","primaryCompletion":"2011-03-16","completion":"2011-03-16","firstPosted":"2008-10-01","resultsPosted":"2012-03-22","lastUpdate":"2021-06-14"},"enrollment":336,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["ADHD"],"interventions":[{"type":"DRUG","name":"Lisdexamfetamine Dimesylate (LDX)","otherNames":["Vyvanse™"]},{"type":"DRUG","name":"Methylphenidate Hydrochloride","otherNames":["Concerta®, OROS MPH"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Lisdexamfetamine Dimesylate (LDX)","type":"EXPERIMENTAL"},{"label":"Methylphenidate Hydrochloride","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main aim of this study is to see if giving LDX to children and adolescents aged 6-17 years with ADHD decreases symptoms of ADHD.","primaryOutcome":{"measure":"Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 7 Weeks","timeFrame":"Baseline and up to 7 weeks","effectByArm":[{"arm":"Lisdexamfetamine Dimesylate (LDX)","deltaMin":-24.3,"sd":1.16},{"arm":"Methylphenidate Hydrochloride","deltaMin":-18.7,"sd":1.14},{"arm":"Placebo","deltaMin":-5.7,"sd":1.13}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":49,"countries":["Belgium","France","Germany","Hungary","Italy","Netherlands","Poland","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["23332456","23708466","23893527","26409610"],"seeAlso":["http://www.fda.gov/opacom/7alerts.html"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":111},"commonTop":["Headache","Decreased appetite","Nasopharyngitis","Insomnia","Abdominal upper pain"]}}